A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Cooling

Event context and recent stock move

Indivior Pharmaceuticals (INDV) has been attracting attention after a mixed stretch in its share price, with the stock up over the past year but down over the past month. This has prompted fresh interest in its valuation.

See our latest analysis for Indivior Pharmaceuticals.

At a share price of $37.39, Indivior Pharmaceuticals has seen momentum cool in the past month with a 30 day share price return down 5.34%, even though the 90 day share price return is up 12.15% and the 1 year total shareholder return is very large.

If you are comparing Indivior with other opportunities in healthcare and drug development, it can be useful to see what else is gaining attention in related areas, starting with 39 healthcare AI stocks

So, with the stock cooling in the short term but showing a very large 1-year total return and trading at a reported intrinsic discount, is Indivior Pharmaceuticals undervalued today, or is the market already pricing in future growth?

Most Popular Narrative: 1.2% Undervalued

Against a last close of $37.39, the most followed narrative pegs Indivior Pharmaceuticals’ fair value at about $37.86. This leaves only a small implied upside that still depends heavily on how its opioid use disorder franchise plays out.

The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.

Read the complete narrative.

Curious what has to happen for that fair value to hold up? The narrative leans on tighter costs, higher margins and specific revenue and earnings paths. The exact hurdle rates might surprise you.

Result: Fair Value of $37.86 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, analysts also flag that stronger SUBLOCADE uptake, or more effective cost savings and Rest of World optimization, could shift earnings well beyond what this fair value assumes.

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Next Steps

With the story so finely balanced between concerns and optimism, it makes sense to check the data for yourself and move quickly while sentiment is split. To see both sides laid out clearly, start with the 4 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you might miss opportunities that fit your style even better. Use the tools available and widen your field of view.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com